Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.34 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.34 |
| ▸ | SNCA | P37840 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3914600 | 1.00 | ALDH1A1 (0.41) | ALDH1A1CA12CA1CA2CA4 | |
| SCHEMBL2934586 | 0.86 | MEN1 (0.48) | ALDH1A1POLBGAABCHEMEN1 | |
| SCHEMBL2934589 | 0.86 | MEN1 (0.48) | ALDH1A1POLBGAABCHEMEN1 | |
| SCHEMBL9016972 | 0.83 | POLB (0.46) | ALDH1A1CA12CA1CA2CA4 | |
| SCHEMBL2929359 | 0.77 | BCHE (0.40) | ALDH1A1POLBGAABCHEMEN1 | |
| SCHEMBL2929355 | 0.77 | BCHE (0.40) | ALDH1A1POLBGAABCHEMEN1 | |
| SCHEMBL151627 | 0.75 | ALDH1A1 (0.52) | ALDH1A1POLBGAAMEN1KMT2A | |
| SCHEMBL716384 | 0.75 | ALDH1A1 (0.52) | ALDH1A1CA12CA1CA2POLB | |
| SCHEMBL3520495 | 0.71 | POLB (0.48) | ALDH1A1POLBGAABCHEAR | |
| SCHEMBL7076295 | 0.70 | MEN1 (0.54) | BCHEMEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247577-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | ROGEL OLIVIER | 2009-10-01 | — | — | US | disclosed |
| EP-2029544-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007140980-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247577-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | BACE1, BACE2, APP | ALDH1A1 1523/4885CA12 4352/4885CA1 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.